Health News

Circassia's Short-Course House Dust Mite Allergy Treatment Achieves Significant Long-Term Symptom Reduction

Author: Australian Business

OXFORD, England, September 12, 2013 /PRNewswire/ -- Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced successful results from a phase II clinical study of its house dust mite allergy treatment (House Dust Mite-Synthetic Peptide Immuno-Regulatory......

More...

More Articles...

"Anti-Aging Pill" Steals Show at Fashion Week!
arGEN-X Identifies Potent Antibody Antagonists against Complex Chronic Pain Target Nav1.7
Combattre la septicémie pour sauver 800 000 vies chaque année
Frost Sullivan: Shortcomings in Medical Imaging Workflow Severely Impact Radiologists' Productivity
UK collaborates with Alere to transform health service outcomes
Se comercializa en Rusia Halaven® (eribulina), el primer y único tratamiento en monoterapia que aumenta la supervivencia en el último estadio del cáncer de mama metastásico
Halaven® (eribulin), die erste und einzige lebensverlängernde Mono-Chemotherapie bei metastasiertem Brustkrebs im spätstadium, jetzt in Russland erhältlich
ASSA ABLOY Expands Offering for Behavioral Health Door Openings
Historic Agreement Protects Hospital Services, Results in New Federal Funds to Improve Access to Care
ADA Statement on September 12, 2013 Senate Committee Hearing: A Step in the Right Direction toward Improving the Nation's Dental Health

Page 1796 of 1908